|64.01 -1.01 (-1.55%)||12-05 16:00|
|Targets||6-month :||76.59||1-year :||89.46|
|Resists||First :||65.58||Second :||76.59|
|Supports||First :||63.28||Second :||61.86|
|MAs||MA(5) :||64.5||MA(20) :||63.95|
|MA(100) :||66.89||MA(250) :||68.72|
|MACD||MACD :||-0.1||Signal :||-0.3|
|%K %D||K(14,3) :||77.8||D(3) :||80|
|52-week||High :||76.55||Low :||61.72|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AZN ] has closed above bottom band by 47.4%. Bollinger Bands are 49.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.
|If tomorrow:||Open lower||Open higher|
|High:||65.12 - 65.34||65.34 - 65.55|
|Low:||63.94 - 64.24||64.24 - 64.52|
|Close:||64.55 - 64.96||64.96 - 65.34|
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Tue, 05 Dec 2023
AstraZeneca falls Tuesday, underperforms market - MarketWatch
Mon, 04 Dec 2023
AstraZeneca rises Monday, outperforms market - MarketWatch
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||3,100 (M)|
|Shares Float||1,540 (M)|
|Held by Insiders||0 (%)|
|Held by Institutions||17.1 (%)|
|Shares Short||9,010 (K)|
|Shares Short P.Month||5,860 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||24.01|
|Profit Margin||13.1 %|
|Operating Margin||22 %|
|Return on Assets (ttm)||9.2 %|
|Return on Equity (ttm)||16.3 %|
|Qtrly Rev. Growth||4.5 %|
|Gross Profit (p.s.)||11.52|
|Sales Per Share||14.51|
|Qtrly Earnings Growth||-16.3 %|
|Operating Cash Flow||10,360 (M)|
|Levered Free Cash Flow||12,670 (M)|
|Price to Book value||2.66|
|Price to Sales||4.41|
|Price to Cash Flow||19.15|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|